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Despite clinicians' enthusiasm for removing accessory spleens, this operation has produced a remission in less than a third of cases presenting up to 1981.3 Application of our criteria to these cases suggests that half of those with true relapses of idiopathic thrombocytopenic purpura responded while none who failed to respond to splenectomy did. To this latter group may now be added our own two patients. In 1981 Pawelski et al5 described 12 patients with apparently true relapses of the purpura after splenectomy, all of whom were cured by splenunculectomy.5 Purpura that fail to respond to splenectomy should be distinguished from true post splenectomy relapses. This has not been the case in the past. Although the number of children not cured by splenectomy in our centre is small, we believe that criteria such as ours (platelets <150x 109/l within six weeks of splenectomy) may identify a group of patients very unlikely to respond to splenunculectomy. Patients who have had a true relapse of the purpura after apparently successful splenectomy in whom an enlarged accessory spleen is shown may well benefit from its removal.
SUMMARY Pancytopenia after intramuscular irondextran treatment occurred in an infant with Down's syndrome. Haematological abnormalities recurred on subsequent challenge. Positive migration inhibiting factor and mast cell degranulation tests support an allergic pathogenesis for the pancytopenia. These side effects have not been reported previously.
Severe, even fatal, allergic reactions are known to occur after parenteral administration of irondextran (Imferon). We describe a patient who developed thrombocytopenia, leucopenia, and haemolytic anaemia after intramuscular injection of iron-dextran. These haematological abnormalities recurred on subsequent challenge.
Case report A 1 year old girl with Down's syndrome was admitted to our department. Blood count showed an iron deficiency anaemia with haemoglobin concentration 83 g/l, packed cell volume 0-28, mean corpuscular volume 71 fl, leucocytes 8x109/l (70% neutrophils, 12% band forms, 16% lymphocytes, 2% monocytes), and platelets 165 x 109/l. Serum iron concentration was 2-3 mM/l (12-7 [tg%) . Iron binding capacity was 55 mM/l (307 ,ug%). Intramuscular iron-dextran (30 mg/kg) was given in three divided doses over six days because of feeding problems and poor compliance. Ten days later the haemoglobin concentration rose to 98 g/l, and the reticulocyte count was 4-8%. The leucocyte count was 9-7x109/l with normal differential count, and the platelet count was 180x 109/l. She was discharged home but was readmitted to hospital one month later. Her blood count showed pancytopenia with haemoglobin concentrations 74 g/l, packed cell volume 0-24, mean corpuscular volume 85 fl, leucocytes 3-3 x 109/l (49% neutrophils, 4% band forms, 43% lymphocytes, 2% monocytes, and 2% eosinophils), and platelets 50x 109/l ( Figure) . Direct and indirect Coombs' tests were negative, her glucose-6-phosphate concentration was normal, and forms, 26% lymphocytes, 6' eosinophils), and platelets 2 bin concentration dropped al level ( Figure) .
Tests with iron-dextran J migration inhibition factor a tion were positive. Six weekv I Pancytopenia caused by iron-dextran 195 concentration rose spontaneously to 113 g/l, packed cell volume to 0-39, mean corpuscular volume to 103 fl, leucocytes to 8-1x109/l, platelets to 140x109/l, and haptoglobin concentrations to 1-09 g/l (Figure) .
Discussion
Many adverse reactions associated with the adminis-\.* --~|~~t ration of parenteral iron-dextran preparations have been described. l Local reactions may include pain at the injection site, skin discoloration, and local inflammation. An association between intramuscular iron and subsequent development of soft tissue 0?. neutrophils, 11% band been a defective host-defence mechanism induced % monocytes, and 4% by the iron deficiency itself. 2x109/l. The haptogloOur patient developed thrombocytopenia, leucogain to an undetectable penia (neutropenia and lymphopenia), and haemolytic anaemia after intramuscular administration for the presence of a of iron-dextran. These haematological abnormalities nd mast cell degranula-reappeared after a challenge with iron-dextran and s later the haemoglobin were accompanied by positive migration inhibition Ia I aI group.bmj.com on September 30, 2017 -Published by http://adc.bmj.com/ Downloaded from factor and mast cell degranulation, suggesting hypersensitivity to this drug. SUMMARY Thirty preterm infants (birthweight under 1500 g) were treated with phenobarbitone to examine its effectiveness in reducing the incidence of intraventricular haemorrhage (IVH), the control group comprising 28 infants. The treated group had 57% incidence of IVH and mortality of 13% compared with 68% and 14%, respectively, in controls.
Since barbiturates have been shown to have neuroprotective effects several reports have examined the effectiveness of phenobarbitone in the prevention of intraventricular haemorrhage (IVH) in preterm infants. The conflicting results obtained in these trials led us to re-evaluate this issue using the protocol of Donn et al, who showed that phenobarbitone reduced the incidence of IVH.
Subjects and methods
We studied 58 preterm infants (birthweight less than 1500 g) who had no congenital malformations and whose mothers had not received phenobarbitone before their delivery. We randomly allocated these infants into control and treatment groups. The two groups were comparable with respect to birthweight, gestational age, race, sex, mode of delivery, and Apgar score. The control group (n=28, birthweight 1120 (SD 218) g) received supportive care only. The treatment group (n=30, birthweight 1119 (SD 264) g) received phenobarbitone for the first week of life, starting at less than 6 hours of age. We administered phenobarbitone in a loading dose of 20 mg/kg divided into two equal doses administered intravenously 12 hours apart and a maintenance dose of 2-5 mg/kg every 12 hours. We obtained blood concentrations of phenobarbitone before the first maintenance dose and then at 3-5 days of age and adjusted the dose to achieve phenobarbitone trough blood concentrations of 20-30 tg/ml.
We obtained ultrasound brain scans on days 1, 3, and 7 of life and subsequently at weekly intervals in infants with IVH. Haemorrhages were graded as follows: grade 1, germinal matrix haemorrhage; grade 2, intraventricular haemorrhage with normal ventricle size; grade 3, intraventricular haemorrhage with ventricular dilatation; grade 4, intraparenchymal haemorrhage. The data were analysed by Student's t test to compare the means and x2 test to compare the proportions in the two groups. Differences were considered significant if the value of p was 0-05 or less.
Results
The number of infants in the two groups who required assisted ventilation, treatment with bicarbonate, volume expansion, and indomethacin for patent ductus arteriosus was comparable. In addition, the number of infants who developed hypoxia (arterial oxygen tension <40 mm Hg), hypercarbia (arterial carbon dioxide tension >60 mm Hg), or pneumothorax was also similar. Blood concentrations of phenobarbitone (mean (SD)) before the
